Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31...
Newsletter
Error at the newsletter cancelation
There is a mistake occured at the cancelation. Please try again.
Up to Date
Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit...
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn....